Use of modern classification systems for complex diagnostics of Alzheimer’s disease

Zorkina Y.A.

Serbsky National Medical Research Center of Psychiatry and Narcology;
Alexeev Mental-Health Clinic No. 1 of Moscow Healthcare Department

ORCID: 0000-0003-0247-2717

Morozova I.O.

Alexeev Mental-Health Clinic No. 1 of Moscow Healthcare Department

ORCID: 0000-0002-2102-4111

Abramova O.V.

Serbsky National Medical Research Center of Psychiatry and Narcology;
Alexeev Mental-Health Clinic No. 1 of Moscow Healthcare Department

ORCID: 0000-0001-8793-1833

Ochneva A.G.

Serbsky National Medical Research Center of Psychiatry and Narcology;
Alexeev Mental-Health Clinic No. 1 of Moscow Healthcare Department

ORCID: 0000-0003-4182-5503

Gankina O.A.

Alexeev Mental-Health Clinic No. 1 of Moscow Healthcare Department;
Russian Medical Academy of Continuous Professional Education

ORCID: 0000-0002-8714-2698

Andryushenko A.V.

Alexeev Mental-Health Clinic No. 1 of Moscow Healthcare Department;
Lomonosov Moscow State University

ORCID: 0000-0002-7702-6343

Kurmyshev M.V.

Alexeev Mental-Health Clinic No. 1 of Moscow Healthcare Department

ORCID: 0000-0001-7354-7216

Kostyuk G.P.

Alexeev Mental-Health Clinic No. 1 of Moscow Healthcare Department

SPIN RSCI: 3424-4544
Scopus AuthorID: 57200081884
ORCID: 0000-0002-3073-6305

Morozova A.Yu.

Serbsky National Medical Research Center of Psychiatry and Narcology;
Alexeev Mental-Health Clinic No. 1 of Moscow Healthcare Department

ORCID: 0000-0002-8681-5299

Use of modern classification systems for complex diagnostics of Alzheimer’s disease

Authors:

Zorkina Y.A., Morozova I.O., Abramova O.V., Ochneva A.G., Gankina O.A., Andryushenko A.V., Kurmyshev M.V., Kostyuk G.P., Morozova A.Yu.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(1): 121‑127

DOI: 10.17116/jnevro2024124011121

Read: 1809 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Zorkina YA, Morozova IO, Abramova OV, et al. . Use of modern classification systems for complex diagnostics of Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(1):121‑127. (In Russ.)
https://doi.org/10.17116/jnevro2024124011121

Подписка 2025-2 (S.S. Korsakov Journal of Neurology and Psychiatry)

Использование инфографики авторами научных работ

Close metadata

OBJECTIVE

To compare the content of β-amyloid (Aβ) peptides Aβ40, Aβ42, total and threonine phosphorylated 181 tau-protein in cerebrospinal fluid (CSF) of patients with the clinical diagnosis of Alzheimer’s disease (AD).

MATERIAL AND METHODS

The study was performed on 64 patients with a diagnosis of dementia and MMSE scores of 24 or lower. All patients underwent lumbar puncture. Aβ40, Aβ42, Aβ42/40 ratio, total tau, phosphorylated tau at threonine 181 were determined in the CSF using a multiplex assay according to the manufacturer’s protocol, the concentration was determined in pkg/ml.

RESULTS

The preliminary diagnosis of AD was made in 3 patients (5%). As a result of the study of protein content in the CSF, signs of AD were detected in 48 (75%) people. The findings suggest that the diagnosis of AD is made 10—14 times less frequently than it should be according to the World Health Organization data. The discrepancy between clinical diagnosis and laboratory findings is confirmed by our study.

CONCLUSION

Differences in the therapy of dementias and the development of new drugs targeting specific links in the pathogenesis of different types of dementias require accurate and complete diagnosis of dementias, especially AD, as the most common type of dementia.

Keywords:

dementia

cerebrospinal fluid

beta-amyloid

tau-protein

Authors:

Zorkina Y.A.

Serbsky National Medical Research Center of Psychiatry and Narcology;
Alexeev Mental-Health Clinic No. 1 of Moscow Healthcare Department

ORCID: 0000-0003-0247-2717

Morozova I.O.

Alexeev Mental-Health Clinic No. 1 of Moscow Healthcare Department

ORCID: 0000-0002-2102-4111

Abramova O.V.

Serbsky National Medical Research Center of Psychiatry and Narcology;
Alexeev Mental-Health Clinic No. 1 of Moscow Healthcare Department

ORCID: 0000-0001-8793-1833

Ochneva A.G.

Serbsky National Medical Research Center of Psychiatry and Narcology;
Alexeev Mental-Health Clinic No. 1 of Moscow Healthcare Department

ORCID: 0000-0003-4182-5503

Gankina O.A.

Alexeev Mental-Health Clinic No. 1 of Moscow Healthcare Department;
Russian Medical Academy of Continuous Professional Education

ORCID: 0000-0002-8714-2698

Andryushenko A.V.

Alexeev Mental-Health Clinic No. 1 of Moscow Healthcare Department;
Lomonosov Moscow State University

ORCID: 0000-0002-7702-6343

Kurmyshev M.V.

Alexeev Mental-Health Clinic No. 1 of Moscow Healthcare Department

ORCID: 0000-0001-7354-7216

Kostyuk G.P.

Alexeev Mental-Health Clinic No. 1 of Moscow Healthcare Department

SPIN RSCI: 3424-4544
Scopus AuthorID: 57200081884
ORCID: 0000-0002-3073-6305

Morozova A.Yu.

Serbsky National Medical Research Center of Psychiatry and Narcology;
Alexeev Mental-Health Clinic No. 1 of Moscow Healthcare Department

ORCID: 0000-0002-8681-5299

Received:

14.09.2023

Accepted:

16.09.2023

List of references:

Global action plan on the public health response to dementia 2017—2025. Geneva: World Health Organization; 2017. Licence: CC BY-NC-SA 3.0 IGO.
Jeremic D, Jiménez-Díaz L, Navarro-López JD. Past, present and future of therapeutic strategies against amyloid-β peptides in Alzheimer’s disease: a systematic review. Ageing Res Rev. 2021;72:101496. https://doi.org/10.1016/j.arr.2021.101496
MacLeod R, Hillert EK, Cameron RT, Baillie GS. The role and therapeutic targeting of α-, β- and γ-secretase in Alzheimer’s disease. Future Sci OA. 2015;1(3):FSO11. https://doi.org/10.4155/fso.15.9
Murphy MP, LeVine H 3rd. Alzheimer’s disease and the amyloid-beta peptide. J Alzheimers Dis. 2010;19(1):311-323. https://doi.org/10.3233/JAD-2010-1221
Folch J, Ettcheto M, Petrov D, et al. Review of the advances in treatment for Alzheimer disease: Strategies for combating β-amyloid protein. Una revisión de los avances en la terapéutica de la enfermedad de Alzheimer: estrategia frente a la proteína β-amiloide. Neurologia (Engl Ed). 2018;33(1):47-58. https://doi.org/10.1016/j.nrl.2015.03.012
Grandal Leiros B, Pérez Méndez LI, Zelaya Huerta MV, et al. Prevalence and concordance between the clinical and the post-mortem diagnosis of dementia in a psychogeriatric clinic. Prevalencia y concordancia entre diagnóstico clínico y anatomopatológico de demencia en una clínica psicogeriátrica. Neurologia (Engl Ed). 2018;33(1):13-17. https://doi.org/10.1016/j.nrl.2016.04.011
Selvackadunco S, Langford K, Shah Z, et al. Comparison of clinical and neuropathological diagnoses of neurodegenerative diseases in two centres from the Brains for Dementia Research (BDR) cohort. J Neural Transm (Vienna). 2019;126(3):327-337. https://doi.org/10.1007/s00702-018-01967-w
Sengupta U, Kayed R. Amyloid β, Tau, and α-Synuclein aggregates in the pathogenesis, prognosis, and therapeutics for neurodegenerative diseases. Prog Neurobiol. 2022;214:102270. https://doi.org/10.1016/j.pneurobio.2022.102270
Sunderland T, Linker G, Mirza N, et al. Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA. 2003;289(16):2094-2103. https://doi.org/10.1001/jama.289.16.2094
Li RX, Ma YH, Tan L, Yu JT. Prospective biomarkers of Alzheimer’s disease: A systematic review and meta-analysis. Ageing Res Rev. 2022;81:101699. https://doi.org/10.1016/j.arr.2022.101699
Mielke MM, Frank RD, Dage JL, et al. Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes. JAMA Neurol. 2021;78(9):1108-1117. https://doi.org/10.1001/jamaneurol.2021.2293
Folstein MF, Folstein SE, McHugh PR. «Mini-mental state». A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-198. https://doi.org/10.1016/0022-3956(75)90026-6
Ebenau JL, Timmers T, Wesselman LMP, et al. ATN classification and clinical progression in subjective cognitive decline: The SCIENCe project. Neurology. 2020;95(1):e46-e58. https://doi.org/10.1212/WNL.0000000000009724
Hansen EO, Dias NS, Burgos ICB, et al. Millipore xMap® Luminex (HATMAG-68K): An Accurate and Cost-Effective Method for Evaluating Alzheimer’s Biomarkers in Cerebrospinal Fluid. Front Psychiatry. 2021;12:716686. https://doi.org/10.3389/fpsyt.2021.716686.
Constantinides VC, Boufidou F, Bourbouli M, et al. Application of the AT(N) and Other CSF Classification Systems in Behavioral Variant Frontotemporal Dementia. Diagnostics (Basel). 2023;13(3):332. https://doi.org/10.3390/diagnostics13030332.
Jack CR Jr, Bennett DA, Blennow K, et al. A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology. 2016;87(5):539-547. https://doi.org/10.1212/WNL.0000000000002923
Milà-Alomà M, Salvadó G, Gispert JD, et al. Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer’s continuum. Alzheimers Dement. 2020;16(10):1358-1371. https://doi.org/10.1002/alz.12131
Bogolepova AN, Vasenina EE, Gomzyakova NA, et al. Clinical Guidelines for Cognitive Disorders in Elderly and Older Patients. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2021;121(10-3):6-137. (In Russ.). https://doi.org/10.17116/jnevro20211211036
Hasani SA, Mayeli M, Salehi MA, Barzegar Parizi R. A Systematic Review of the Association between Amyloid-β and τ Pathology with Functional Connectivity Alterations in the Alzheimer Dementia Spectrum Utilizing PET Scan and rsfMRI. Dement Geriatr Cogn Dis Extra. 2021;11(2):78-90. https://doi.org/10.1159/000516164
Resnick SM, Sojkova J. Amyloid imaging and memory change for prediction of cognitive impairment. Alzheimers Res Ther. 2011;3(1):3. https://doi.org/10.1186/alzrt62
Jellinger KA, Attems J. Prevalence and pathology of vascular dementia in the oldest-old. J Alzheimers Dis. 2010;21(4):1283-1293. https://doi.org/10.3233/jad-2010-100603
Levin OS, Trusova NA. Vascular risk factors for Alzheimer’s disease. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2013;113(7 Pt 2):3-12. (In Russ.).
Zakharov VV. Differential Diagnosis of Cognitive Impairments. Effektivnaya farmakoterapiya. Nevrologiya. 2014;(3):25. (In Russ.).
Fierini F. Mixed dementia: Neglected clinical entity or nosographic artifice? J Neurol Sci. 2020;410:116662. https://doi.org/10.1016/j.jns.2019.116662
Apátiga-Pérez R, Soto-Rojas LO, Campa-Córdoba BB, et al. Neurovascular dysfunction and vascular amyloid accumulation as early events in Alzheimer’s disease. Metab Brain Dis. 2022;37(1):39-50. https://doi.org/10.1007/s11011-021-00814-4
Badimon A, Torrente D, Norris EH. Vascular Dysfunction in Alzheimer’s Disease: Alterations in the Plasma Contact and Fibrinolytic Systems. Int J Mol Sci. 2023;24(8):7046. https://doi.org/10.3390/ijms24087046
Hort J, O’Brien JT, Gainotti G, et al. EFNS guidelines for the diagnosis and management of Alzheimer’s disease. Eur J Neurol. 2010;17(10):1236-1248. https://doi.org/10.1111/j.1468-1331.2010.03040.x
Gavrilova SI, Kolykhalov IV, Kulik AS, et al. Clinical experience of the use of memantal in patients with moderate and severe Alzheimer’s disease. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2016;116(2):52-57. (In Russ.). https://doi.org/10.17116/jnevro20161162152-57
Olivares D, Deshpande VK, Shi Y, et al. N-methyl D-aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer’s disease, vascular dementia and Parkinson’s disease. Curr Alzheimer Res. 2012;9(6):746-758. https://doi.org/10.2174/156720512801322564
Kokkinou M, Beishon LC, Smailagic N, et al. Plasma and cerebrospinal fluid ABeta42 for the differential diagnosis of Alzheimer’s disease dementia in participants diagnosed with any dementia subtype in a specialist care setting. Cochrane Database Syst Rev. 2021;2(2):CD010945. https://doi.org/10.1002/14651858.CD010945.pub2

Close metadata